Table 6:
Risk standardized outcome (point estimates and 95% confidence intervals) in Ontario and New York adjusted for demographics, neighborhood income, hospital procedure volume, and hospital length of stay
| EVAR | LVAD | TAVR | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Ontario | NY | P-value | Ontario | NY | P-value | Ontario | NY | P-value | |
| Hospital LOS, days (95% Confidence Intervals)* | 4.4 (3.8–5.0) | 3.7 (3.4–4) | 0.055 | 70.9 (58.8–82.9) | 39.2 (32.8–45.6) | <.001 | 10.4 (8.8–11.9) | 8.7 (8.2–9.3) | 0.050 |
| Readmission within 90-days of discharge, % (95% Confidence Intervals) | 11.4 (9.2–14.1) | 16.4 (14.2–19.0) | 0.090 | 37.5 (16.1–65.2) | 67.8 (46.4–99.0) | 0.841 | 20.1 (15.9–25.1) | 25.4 (20.9–30.8) | 0.951 |
| Mortality† | |||||||||
| In-hospital mortality, % (95% Confidence Intervals) | 2.7 (1.7–4.2) | 0.7 (0.4–1.2) | <.001 | 37.4 (15.2–66.6) | 4.1 (1.6–10.6) | 0.001 | 5.3 (3.2–8.5) | 2.1 (1.3–3.5) | 0.009 |
| Mortality within 7-days of procedure, Model 1,% (95% Confidence Intervals) | 1.6 (1.2–2.0) | 1.0 (0.8–1.3) | 0.029 | 8.4(4.2–15.9) | 2.6 (1.4–5) | 0.015 | 2.9(2.1–3.9) | 1.4 (1–1.8) | 0.001 |
| Mortality within 7-days of procedure, Model 2,% (95% Confidence Intervals) | 1.6 (1.2–2.1) | 0.8 (0.6–1.2) | 0.007 | 7.6 (4.0–14.0) | 2.4 (1.1–4.9) | 0.020 | 2.6(1.8–3.7) | 1.5 (0.8–2.8) | 0.147 |
| Mortality within 7-days of procedure, Model 3,% (95% Confidence Intervals) | 1.5 (1.2–2.1) | 0.8 (0.6–1.2) | 0.009 | 6.8 (3.5–12.6) | 3.8 (1.8–7.8) | 0.245 | 2.6(1.7–3.9) | 1.5 (0.8–2.9) | 0.164 |
Expected LOS for reference case derived from (age= mean age ON, sex= male, procedure volume= mean procedure volume ON, income group = 1st or 2nd quintile) based on GEE fits for each region.
Probability for reference case for mortality derived from (age= mean age ON, sex= male, procedure volume= mean procedure volume ON, income group = 1st or 2nd quintile, LOS= 1st quartile per ON) based on GEE fits for each region. For mortality within 7-days of procedure Model 1 adjusted for hospital volume, Model 2 for comorbidities listed in Table 1, Model 3 for volume plus comorbidity with the reference cases the same as described above.